OBJECTIVE: To evaluate whether bone loss occurs over time in pre-menopausal systemic lupus erythematosus (SLE) patients. METHODS: We performed a longitudinal bone mineral density (BMD) analysis in a group of 35 pre-menopausal female SLE patients. Lumbar spine and hip (total and sub-regions) BMDs were measured twice 21 +/- 11 (mean +/- S.D.) months apart by dual-energy X-ray absorptiometry. RESULTS: In the whole cohort of SLE patients, significant bone loss was observed at the lumbar spine (-1.22%/yr) but not at the total hip. Further analyses indicated that lumbar spine bone loss (-2.12%/yr) occurred exclusively in the subgroup of patients who had taken a mean prednisolone daily dose >7.5 mg between the two BMD measurements. Moreover, bone loss was more important in patients who had previously received a cumulative prednisolone dose </=5 g by the time of their first BMD evaluation. CONCLUSIONS: These results, by demonstrating a loss of lumbar spine bone over time in pre-menopausal SLE patients given glucocorticoid (GC) therapy, strongly support the use of preventive treatment to minimize GC-induced osteoporosis in pre-menopausal female SLE patients given prednisolone daily doses >7.5 mg.
OBJECTIVE: To evaluate whether bone loss occurs over time in pre-menopausal systemic lupus erythematosus (SLE) patients. METHODS: We performed a longitudinal bone mineral density (BMD) analysis in a group of 35 pre-menopausal female SLEpatients. Lumbar spine and hip (total and sub-regions) BMDs were measured twice 21 +/- 11 (mean +/- S.D.) months apart by dual-energy X-ray absorptiometry. RESULTS: In the whole cohort of SLEpatients, significant bone loss was observed at the lumbar spine (-1.22%/yr) but not at the total hip. Further analyses indicated that lumbar spine bone loss (-2.12%/yr) occurred exclusively in the subgroup of patients who had taken a mean prednisolone daily dose >7.5 mg between the two BMD measurements. Moreover, bone loss was more important in patients who had previously received a cumulative prednisolone dose </=5 g by the time of their first BMD evaluation. CONCLUSIONS: These results, by demonstrating a loss of lumbar spine bone over time in pre-menopausal SLEpatients given glucocorticoid (GC) therapy, strongly support the use of preventive treatment to minimize GC-induced osteoporosis in pre-menopausal female SLEpatients given prednisolone daily doses >7.5 mg.
Authors: L P C Seguro; C B Casella; V F Caparbo; R M Oliveira; A Bonfa; E Bonfa; R M R Pereira Journal: Osteoporos Int Date: 2014-08-22 Impact factor: 4.507
Authors: J Jacobs; L-A Korswagen; A M Schilder; L H van Tuyl; B A C Dijkmans; W F Lems; A E Voskuyl; I E M Bultink Journal: Osteoporos Int Date: 2012-10-03 Impact factor: 4.507
Authors: Gabriela Schmajuk; Edward Yelin; Eliza Chakravarty; Lorene M Nelson; Pantelis Panopolis; Jinoos Yazdany Journal: Arthritis Care Res (Hoboken) Date: 2010-07 Impact factor: 4.794